CSL Vifor: Kapruvia approved in Switzerland with additional

Kapruvia (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently

Related Keywords

Australia , Melbourne , Victoria , Canada , United Kingdom , Switzerland , Singapore , Christopher Posner , Iris Francesconi , Thomas Hutter , Klaus Henning Jensen , Annie Spinetta , Instagram , Linkedin , Twitter , Drug Administration , International Journal Of Nephrology , Nasdaq , Regulatory Agency , Exchange Commission , Cara Therapeutics Inc , Access Consortium , National Registry Study , European Medicines Agency , Health Canada , Swiss Agency For Therapeutic Products Swissmedic , Fresenius Medical Care , Fresenius Medical Care Renal Pharma , Cara Therapeutics , Swiss Agency , Therapeutic Products , United Kingdom Medicines , Chief Medical Officer , Chief Executive Officer , New England Journal , Vifor Fresenius Medical Care Renal Pharma , Registry Study , Private Securities Litigation Reform Act , Quarterly Report , Dialysis Outcomes , Practice Patterns , Nephrol Dial , Patient Reported Outcomes , Uremic Pruritus , Media Contact , Vifor , Apruvia , Approved , Dditional , Egulatory , Decisions , Xpected , 022 ,